 "Dr Reddy's partners Gland Pharma in the US to market injectables")
Dr Reddy’s Laboratories Ltd (DRL) has entered into a strategic collaboration with Gland Pharma - a developer and manufacturer of sterile dosage forms - to market and distribute a diverse portfolio of eight injectable abbreviated new drug applications (ANDAs). The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the US.
The combined sale of branded and generic versions of the products – that the two companies are aiming to target through this alliance - in the US is approximately $ 1 billion MAT for the most recent twelve months ending in August 2016, according to IMS Health.
Alok Sonig, executive vice president and head of North America, DRL, said, “We are excited about this opportunity. Dr Reddy’s Laboratories has a strong track record in developing, marketing and distributing generic injectables in the US. Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term.”
Srinivas Sadu, chief operating officer of Gland Pharma, added, “We are happy to expand our collaboration with Dr Reddy’s for marketing and distribution of Gland Products in US and other ex-US markets. Dr Reddy’s has an impressive track record of commercialising injectables products in the US, and we are confident that our partnership will continue to grow.”
Dr Reddy's is aggressively developing its US injectable business and recently launched paricalcitol injection, a therapeutic equivalent generic version of Zemplar.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%